Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/08—Antibacterial agents for leprosy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

• the present invention relates to new tetrahydropyridyl-alkyl-heterocycles, the pharmaceutical compositions containing them and a process for their preparation.
• EP-164633 describes tetrahydropyridines, substituted by a 4-indolyl radical, showing activity in the central nervous system. It has now been found that certain phenyl- and pyridyltetrahydropyridines, substituted by nitrogen heterocycles, have a potent activity with respect to the modulation of TNF-alpha (from the Tumor Necrosis Factor).
• TNF-alpha is a cytokine which has recently aroused interest as a mediator of immunity, inflammation, cell proliferation, fibrosis etc. This mediator is abundantly present in the inflamed synovial tissue and plays an important role in the pathogenesis of autoimmunity.
• the present invention relates, according to one of its aspects, to tetrahydropyridyl-alkyl-heterocycles of formula (I):
• X represents N or CH
• Ri represents a hydrogen or halogen atom or a group
• R 2 and R 3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a nitrogen heterocycle of formula (a) - (l)
• R ", R 5 and R ⁇ each independently represent a hydrogen atom or a (CC) alkyl group; the dotted lines represent single or double bonds; R 7 and R "each independently represent a hydrogen or halogen atom, a (C ⁇ -C 4 ) alkyl or (C ⁇ -C) alkoxy group; as well as their N-oxides and their salts or solvates, provided that when X is CH, then (a) is not an indol-4-yl residue.
• (C ⁇ -C 4 ) alkyl denotes a monovalent radical of a saturated straight or branched chain Cj-C hydrocarbon and the term "(C ⁇ -C) alkoxy” denotes a monovalent radical d 'a straight or branched chain saturated Cj-C hydrocarbon linked via an oxygen atom.
• halogen denotes an atom chosen from chlorine, bromine, iodine and fluorine.
• heterocycles (a) to (d) represent aromatic heterocycles.
• Preferred compounds of formula (I) are those where n is zero.
• Other preferred compounds are those where R 2 and R 3 are each a hydrogen atom.
• Ri is a group CF 3 .
• X is CH and Ri is in the 2 or 3 position of benzene.
• Rt, R5 and R ⁇ each represent a hydrogen or a methyl group.
• R 7 and R 8 each represent a hydrogen atom or a (C ⁇ -C) alkyl group.
• A is a radical of formula (a) - (d)
• the compounds where A is a radical of formula (a) being particularly preferred.
• Other preferred compounds are those where A is a radical of formula (a) - (d), in particular the radical (a), and the dotted lines represent double bonds.
• the nuclei of formula (a) - (d) where the dotted lines represent double bonds, may in the present description be called respectively, indole, isoindole, indazole and benzimidazole.
• the nuclei of formula (a) - (d) where the dotted lines represent single bonds may in the present description be called respectively, indoline, isoindoline, indazoline and benzimidazoline.
• nuclei can be attached to the rest of the molecule of formula (I) by any of the carbon atoms in positions 4, 5, 6 or 7.
• the nuclei of formula (e) - (f) may in the present description be named respectively, tetrahydro-quinoline and tetrahydro-isoquinoline. These nuclei can be attached to the rest of the molecule of formula (I) by any of the carbon atoms in positions 5, 6, 7 or 8.
• nuclei of formula (g) - (l) may in the present description be alternatively called either 1,2-, 1,3-, 1,4- and 2,3-benzodiazines or, respectively, cinnoline, quinazoline, quinoxaline and phthalazine.
• benzodiazines can be attached to the rest of the molecule of formula (I) by any of the carbon atoms in positions 5, 6, 7 or 8.
• the compounds of formula (I) can exist as N-oxide derivatives.
• the compounds of formula (I) may in particular carry the N-oxide group on tetrahydropyridine or else on one or both of the nitrogen groups (a) - (l), or all the nitrogen present can be simultaneously oxidized.
• the salts of the compounds of formula (I) according to the present invention also include the addition salts with pharmaceutically acceptable inorganic or organic acids such as the hydrochloride, the hydrobromide, the sulfate, the hydrogen sulfate, the dihydrogen phosphate, the citrate, maleate, tartrate, fumarate, gluconate, methanesulfonate, 2-naphthalenesulfonate, etc., than addition salts which allow proper separation or crystallization of the compounds of formula (I), such as picrate, oxalate or addition salts with optically active acids, for example camphosulfonic acids and mandelic or substituted mandelic acids.
• Optically pure stereoisomers, as well as mixtures of isomers of the compounds of formula (I), due to asymmetric carbon, when one of R 2 and R 3 is methyl and the other hydrogen, in any proportion, are part of the present invention.
• the compounds of formula (I) can be prepared by a condensation reaction starting from a compound of formula (II):
• the condensation reaction is normally carried out by mixing the starting compounds (II) and (III) in an inert organic solvent, according to conventional methods.
• inert organic solvent a solvent which does not interfere with the reaction.
• solvents are, for example, alcohols such as methanol, ethanol, isopropanol or butanol, or ketones, such as isobutylmetilketone, the latter being a particularly preferred solvent.
• leaving group L it is possible, for example, to use a chlorine or bromine atom or else a mesyloxy group (CH 3 -SO -O-).
• the reaction is carried out at a temperature between -10 ° C. and the reflux temperature of the reaction mixture, the reflux temperature being preferred.
• the reaction can be suitably carried out in the presence of a proton acceptor, for example an alkali carbonate or a tertiary amine such as triethylamine.
• a proton acceptor for example an alkali carbonate or a tertiary amine such as triethylamine.
• the reaction is normally terminated after a few hours, normally 1 to 12 hours are sufficient to complete the condensation.
• the desired compound is isolated according to conventional techniques in the form of a free base or of a salt thereof.
• the free base can be transformed into one of its salts by simple salification in an organic solvent such as an alcohol, preferably ethanol or isopropanol, an ether such as 1,2-dimethoxyethane, ethyl acetate , acetone or a hydrocarbon such as hexane.
• the compound of formula (I) obtained is isolated according to the usual techniques and optionally transformed into one of its salts or solvates or into its N-oxide derivatives.
• the starting compounds of formula (II) are known or they can be prepared analogously to the known compounds.
• the starting compounds of formula (III) are known or they can be prepared from the corresponding acids or esters, by reduction of the carboxylic group to alcohol group and substitution of OH by the desired group L according to conventional methods. Examples of such reactions are recorded in the experimental part.
• the starting compounds of formula (III) can be prepared by reaction of the organometallic derivatives of the nuclei (a) - (l) of formula (IV)
• M represents a metal radical and A is as defined above, with a suitable cyclic ether, to obtain the alcohol of formula (V)
• metal radical is meant according to the present invention, a radical containing at least one metal and which is capable of opening a suitable cyclic ether in order to give the alcohol of formula (V).
• Suitable compounds of formula (IV) are for example the Grignard compounds of formula Hal-Mg-A and cuprates Hal-Cu-A, where Hal is as defined above, as well as lithium derivatives Li-A, etc.
• organometallic compounds of formula (IV) are prepared according to well known techniques, for example from halogen derivatives of the nuclei
• the cyclic ethers are chosen according to the compound of formula (I) which it is desired to obtain.
• the appropriate cyclic ether is ethylene oxide.
• ketones or aldehydes can be used instead of the cyclic ethers.
• the compounds of formula (I) can also be prepared by a process which provides: (a) to react the compound of formula (VI):
• step (a) can be conveniently carried out in an organic solvent at a temperature between -10 ° C and the reflux temperature of the reaction mixture.
• BOP tri (dimethylamino) benzotriazol-1 -yloxyphosphonium hexafluorophosphate
• anhydride a mixed anhydride
• an active ester or an acid halide preferably bromide.
• active esters p-nitrophenyl ester is particularly preferred, but methoxyphenyl, trityl, benzhydryl esters and the like are also suitable.
• a halogenated solvent such as methylene chloride, dichloroethane, 1, 1, 1 -trichloroethane, chloroform and the like, but also other organic solvents compatible with the reagents used, for example for example dioxane, tetrahydrofuran or a hydrocarbon such as hexane, can also be used.
• the reaction can be suitably carried out in the presence of a proton acceptor, for example an alkali carbonate or a tertiary amine such as triethylamine.
• step (b) can be suitably carried out by suitable reducing agents such as borane complexes, for example borane dimethylsulfide ([CH 3 ] S-BH 3 ), aluminum hydrides or a complex hydride of lithium and aluminum in an inert organic solvent at a temperature between 0 ° C. and the reflux temperature of the reaction mixture, according to the usual techniques.
• suitable reducing agents such as borane complexes, for example borane dimethylsulfide ([CH 3 ] S-BH 3 ), aluminum hydrides or a complex hydride of lithium and aluminum in an inert organic solvent at a temperature between 0 ° C. and the reflux temperature of the reaction mixture, according to the usual techniques.
• inert organic solvent a solvent which does not interfere with the reaction.
• solvents are, for example, ethers, such as diethyl ether, tetrahydrofuran (THF), dioxane or 1,2-dimethoxyethane.
• ethers such as diethyl ether, tetrahydrofuran (THF), dioxane or 1,2-dimethoxyethane.
• THF tetrahydrofuran
• dioxane dioxane
• 1,2-dimethoxyethane 1,2-dimethoxyethane
• protecting groups it is possible to use the usual protecting groups for nitrogen atoms such as for example tert-butoxycarbonyl, acetyl, benzyloxycarbonyl or tri-isopropyl-silyl, the latter being particularly preferred. These protective groups are finally cleaved to give the compounds of formula (I).
• the compounds of formula (I) carrying an N-oxide group on the nitrogen atoms of the groups (a) - (l) can be prepared from the N-oxide derivatives of the compounds of formula (VII).
• the compounds of formula (I) carrying an N-oxide group on the nitrogen atom of tetrahydropyridine can be prepared by oxidation of the corresponding compounds of formula (I).
• the compound of formula (I) as obtained for example by the above synthesis is subjected to an oxidation reaction according to conventional methods, for example to a reaction with w-chloro acid perbenzoic in a suitable solvent and isolated according to the usual techniques well known to those skilled in the art.
• the compounds of the invention have advantageous properties with respect to the inhibition of TNF- ⁇ .
• LPS lipopolysaccharide
• the test products are administered orally to groups of 5 female Balb / c mice (Charles River, France) aged 7 to 8 weeks. One hour later, the LPS is administered intravenously (10 ⁇ g / mouse). The blood of each animal is taken 1.5 hours after administration of the LPS. The samples are centrifuged, the plasma is recovered and frozen at -80 ° C. TNF- ⁇ is measured using commercial kits (R&D, Abingdon, UK).
• the compounds of formula (I) can be used to treat atherosclerosis, autoimmune diseases, diseases which cause demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases , pulmonary idiopathic fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption, osteoporosis, Paget's disease, multiple myeloma, uveoretinitis, septic shock , sepsis, endotoxin shock, graft versus host reaction, transplant rejection, adult respiratory distress syndrome, silicosis, asbestosis, pulmonary sarcoidosis, Crohn's disease, colitis ulcerative, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, hemodynamic shock, ischemic
• the compounds of formula (I) and their pharmaceutically acceptable salts and solvates are preferably administered orally.
• the active principle can be administered in unit forms administration, mixed with conventional pharmaceutical carriers, to animals and humans for the treatment of the aforementioned conditions.
• Suitable unit dosage forms include, for example, possibly scored tablets, capsules, powders, granules and oral solutions or suspensions.
• the main active ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
• a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like.
• the tablets can be coated with sucrose or other suitable materials or else they can be treated in such a way that they have a prolonged or delayed activity and that they continuously release a predetermined quantity of active principle.
• a preparation in capsules is obtained by mixing the active ingredient with a diluent and by pouring the mixture obtained into soft or hard capsules.
• a preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
• a sweetener preferably calorie-free, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and an appropriate color.
• Water dispersible powders or granules may contain the active ingredient in admixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or correctors taste.
• the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
• the active principle can also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.
• the amount of active ingredient to be administered depends as always on the degree of progression of the disease as well as on the age and weight of the patient.
• the unit doses generally comprise from 0.001 to 100 mg, better still from 0.01 to 50 mg, preferably from 0.1 to 20 mg of active principle, advantageously from 0.5 to 10 mg.
• the present invention relates to a combination comprising a compound of formula (I) or one of its salts or solvates pharmaceutically acceptable, and at least one compound chosen from immunosuppressive agents, such as interferon beta-lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
• immunosuppressive agents such as interferon beta-lb; adrenocorticotropic hormone; glucocorticoids such as prednisone or methylprednisolone; interleukin-1 inhibitors.
• the invention relates to a combination comprising a compound of formula (I), or one of its pharmaceutically acceptable salts or solvates and at least one compound chosen from roquinimex (1,2-dihydro-4-hydroxy-N , l-dimethyl-2-oxo-3-quinolinecarboxanilide), myloran (product of the company Autoimmune containing bovine myelin), antegren (human monoclonal antibody from the companies Elan / Athena Neuro sciences) beta interferon recombinant.
• roquinimex 1,2-dihydro-4-hydroxy-N , l-dimethyl-2-oxo-3-quinolinecarboxanilide
• myloran product of the company Autoimmune containing bovine myelin
• antegren human monoclonal antibody from the companies Elan / Athena Neuro sciences
• association consisting of a compound of formula (I) or one of its pharmaceutically acceptable salts or solvates and a potassium channel blocker, such as for example fampridine (4-aminopyridine).
• the invention relates to a method of treatment of diseases linked to immune and inflammatory disorders as well as in the treatment of pain, in particular atherosclerosis, autoimmune diseases, diseases which cause the demyelination of neurons (such as multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout, bone and cartilage resorption, l osteoporosis, Paget's disease, multiple myeloma, uveoretinitis, septic shock, sepsis, endotoxin shock, graft versus host reaction, transplant rejection, adult respiratory distress syndrome , silicosis, asbestosis, pulmonary sarcoidosis, Crohn's disease, ulcerative colitis, amyotrophic lateral sclerosis, Alzheimer's disease, m
• TlPSiCl triisopropyl-silyl chloride
• the mixture is stirred at -78 ° C for 15 minutes then at room temperature overnight.
• the product is purified by chromatography on a column of silica gel, eluting with hexane. 3 g of the product thus obtained are dissolved in 30 ml of THF at -78 ° C. and 13.4 ml of BuLi in 1.6N solution in hexane (21.5 mmol) are added thereto.
• the mixture is stirred at room temperature for 1 hour, cooled further to -78 ° C. and poured into a suspension of 647 mg of Cul (3.4 mmol) in a mixture of 20 g of ethylene oxide and 20 ml of THF, at -78 ° C.
• the mixture is stirred at -40 ° C. for 5 hours and is added thereto, drop by drop, 43 ml of a phosphate buffer solution at pH 7; diluted with 17 ml of cold water and filtered through celite.
• the filtered solution is washed with 43 ml of 5 M NH 3 and with cold water, the organic phase is dried over sodium sulfate and the solvent is evaporated off under reduced pressure.
• tetrabutylammonium fluoride Bu 4 NF • 3H 2 O
• Example 3a 1 g of the product obtained by Example 3a is dissolved in 18 ml of anhydrous THF and under a stream of nitrogen, the mixture is refluxed for 30 minutes and added to it

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Virology (AREA)
• Immunology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Rheumatology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Neurosurgery (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pulmonology (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Molecular Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Urology & Nephrology (AREA)
• Biotechnology (AREA)
• Hospice & Palliative Care (AREA)
• Ophthalmology & Optometry (AREA)
• Transplantation (AREA)
• Psychiatry (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26212980

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (4)

Citations (3)

• 2002
  • 2002-04-19 US US10/475,460 patent/US7186720B2/en not_active Expired - Fee Related
  • 2002-04-19 WO PCT/FR2002/001343 patent/WO2002085888A1/fr not_active Ceased
  • 2002-04-19 JP JP2002583415A patent/JP4324382B2/ja not_active Expired - Fee Related
  • 2002-04-19 DE DE60220779T patent/DE60220779T2/de not_active Expired - Lifetime
  • 2002-04-19 AT AT02727676T patent/ATE365162T1/de not_active IP Right Cessation
  • 2002-04-19 EP EP02727676A patent/EP1383762B1/fr not_active Expired - Lifetime

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events